Last reviewed 2026-04-23 · How we verify

Trametinib tablet

Trametinib is a MEK inhibitor that blocks the activity of MEK1 and MEK2 enzymes, which are involved in the MAPK/ERK signaling pathway.

Trametinib is a MEK inhibitor that blocks the activity of MEK1 and MEK2 enzymes, which are involved in the MAPK/ERK signaling pathway. Used for Metastatic melanoma, Unresectable or metastatic melanoma.

At a glance

Mechanism of action

This pathway is crucial for cell division and growth, and its dysregulation is associated with various cancers. By inhibiting MEK1 and MEK2, trametinib reduces tumor growth and proliferation.

Approved indications

• Metastatic melanoma
• Unresectable or metastatic melanoma

Common side effects

• Dermatologic reactions
• Fatigue
• Hypophosphatemia
• Nausea
• Diarrhea
• Abdominal pain
• Headache
• Rash
• Vomiting

Key clinical trials

• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors (PHASE1)
• Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma (PHASE2)
• DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. (PHASE2, PHASE3)
• A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration (PHASE1, PHASE2)
• Dabrafenib and/or Trametinib Rollover Study (PHASE4)
• A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) (PHASE1)
• A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer (PHASE1)
• Molecular Profiling of Advanced Soft-tissue Sarcomas (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.